PMID: 15243215Jul 10, 2004Paper

Combination therapy in the management of complex dyslipidemias

Current Opinion in Lipidology
Michael H Davidson, Peter P Toth

Abstract

Patients with dyslipidemias continue to be undertreated in both the primary and secondary prevention settings. Many patients have therapeutic needs that exceed simple reductions in low-density lipoprotein levels using statins. This review discusses the need for comprehensive management of all abnormalities in a given patient's lipoprotein profile and for the use of combinations of anti-lipidemic medications, when indicated. The majority of high-risk patients with manifestations of atherosclerotic disease or who have a coronary artery disease risk equivalent are not meeting their various lipoprotein targets. There is considerable reluctance to titrate statins and to use combinations of anti-lipidemic medications in patients not reaching their various lipoprotein targets. Combinations of anti-lipidemic medications can be specifically tailored to address abnormalities in multiple lipoprotein fractions. Recent clinical trials clearly demonstrate that combination therapy is well tolerated and facilitates lipoprotein goal attainment. Therapeutic approaches that incorporate the use of multiple anti-lipidemic medications should be more widely adopted in order to increase the number of patients able to meet their lipoprotein goals and t...Continue Reading

References

Jan 27, 1975·JAMA : the Journal of the American Medical Association
Jul 4, 1990·JAMA : the Journal of the American Medical Association·L R PierceT P Gross
Oct 1, 1988·Annals of Internal Medicine·R A Levine
Oct 1, 1988·Annals of Internal Medicine·P Reaven, J L Witztum
Jul 13, 1995·The American Journal of Cardiology·J D SpenceH E Khouri
Sep 1, 1994·The American Journal of Cardiology·R S Rosenson, W A Frauenheim
Mar 2, 1994·JAMA : the Journal of the American Medical Association·J M McKenneyV M Chinchili
Jan 1, 1993·The American Journal of Medicine·O WiklundS O Olofsson
Jan 1, 1997·The American Journal of Cardiology·M H DavidsonJ A Tobert
Apr 4, 1998·The American Journal of Cardiology·R L Ellen, R McPherson
Feb 4, 1999·Clinical Cardiology·E A Iliadis, R S Rosenson
Feb 9, 2000·Pharmacology & Therapeutics·A CorsiniF Bernini
Sep 8, 2000·Clinical Pharmacology and Therapeutics·J T BackmanP J Neuvonen
Nov 4, 2000·Expert Opinion on Investigational Drugs·M H DavidsonR M Kleinpell
Dec 21, 2000·Current Atherosclerosis Reports·M H Davidson
Apr 11, 2001·Atherosclerosis·V G AthyrosA G Kontopoulos
Sep 28, 2001·The Annals of Pharmacotherapy·M A OmarT S Cox
Jan 5, 2002·The New England Journal of Medicine·B G BrownJ J Albers
Jan 5, 2002·Expert Opinion on Investigational Drugs·Michael H Davidson
Jan 16, 2002·JAMA : the Journal of the American Medical Association·Earl S FordWilliam H Dietz
Mar 20, 2002·The American Journal of Cardiology·Jonathan IsaacsohnDavid Orloff
Mar 22, 2002·Heart·N A Boon, P Bloomfield
May 23, 2002·The Journal of Pharmacology and Experimental Therapeutics·Thomayant PrueksaritanontThomas A Baillie
Jul 27, 2002·Journal of the American College of Cardiology·Richard C PasternakUNKNOWN National Heart, Lung and Blood Institute
Aug 2, 2002·Current Opinion in Lipidology·Marc Evans, Alan Rees
Sep 19, 2002·British Journal of Clinical Pharmacology·Teddy KosoglouMelton B Affrime
Nov 9, 2002·The American Journal of Cardiology·Claude GagnéUNKNOWN Ezetimibe Study Group
Nov 9, 2002·The American Journal of Cardiology·Carlos A DujovneUNKNOWN Ezetimibe Study Group
Dec 31, 2002·Journal of the American College of Cardiology·Michael H DavidsonEnrico P Veltri
Feb 15, 2003·The American Journal of Cardiology·Boris KerznerUNKNOWN Ezetimibe Study Group
May 16, 2003·JAMA : the Journal of the American Medical Association·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
May 21, 2003·Circulation·Jonathan MyersVictor Froelicher
Aug 9, 2003·Expert Opinion on Drug Safety·Michael H Davidson
Dec 17, 2003·The American Journal of Cardiology·Philip T SagerUNKNOWN Ezetimibe Study Group
Mar 5, 2004·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN REVERSAL Investigators

❮ Previous
Next ❯

Citations

Sep 1, 2007·Current Treatment Options in Cardiovascular Medicine·Anne Carol Goldberg
Feb 24, 2007·Vascular Health and Risk Management·James M BackesPatricia A Howard
Oct 28, 2008·Current Cardiology Reports·Peter P Toth
Feb 17, 2009·Endocrinology and Metabolism Clinics of North America·Runhua Hou, Anne Carol Goldberg
Feb 24, 2007·Pharmacotherapy·James M BackesPatrick M Moriarty
Nov 18, 2005·The American Journal of Cardiology·David G Orloff
Jul 11, 2007·Current Opinion in Lipidology·John R Guyton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carotid Artery Diseases

Carotid artery disease is a group of pathological conditions of the carotid artery. Discover the latest research on carotid artery disease here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.